首页> 美国卫生研究院文献>BMJ Open Access >Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

【2h】

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

机译：由于无反应和/或研究设计患者的临床结局从阿达木单抗转为Baricitinib：类风湿关节炎患者的III期数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme.

机译：目的评估在第三阶段方案中将治疗从阿达木单抗改为口服Janus激酶（JAK）1 / JAK2抑制剂Baricitinib的患者的临床结局。

著录项

期刊名称 BMJ Open Access
作者
Yoshiya Tanaka; Bruno Fautrel; Edward C Keystone; Robert A Ortmann; Li Xie; Baojin Zhu; Maher Issa; Himanshu Patel; Carol L Gaich; Stephanie de Bono; Terence P Rooney; Peter C Taylor;
展开▼
作者单位

展开▼
年(卷),期 -1(78),7
年度 -1
页码 890–898
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
rheumatoid arthritis dmards (biologics) jak inhibitor;

机译：类风湿关节炎;dmards（biologics）;贾克抑制剂;

相似文献

外文文献
中文文献
专利

1. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis [J] . Tanaka Yoshiya, Fautrel Bruno, Keystone Edward C., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019,第7期

机译：由于非反应和/或研究设计，从Adalimumab转换为Baricitinib的患者的临床结果：类风湿性关节炎患者的III期数据
2. Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis [J] . Taylor Peter, Keystone Edward, Ortmann Robert, The Journal of rheumatology . 2017,第6期

机译：从Adalimumab切换到Baricicinib的功效和安全性：类风湿性关节炎患者的第3阶段数据
3. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study [J] . Yue Yang, Jianhua Xu, Jian Xu, Therapeutic advances in musculoskeletal disease. . 2021,第a期

机译：患者报告从随机，双盲，安慰剂控制的结果，对患者的患者的患者患者的AICA III研究，以严重活跃的类风湿性关节炎和对甲氨蝶呤治疗的反应不足：RA-BALLAGE研究结果
4. Immunogenic HLA-DR-presented-peptides Identified from Clinical Samples of Synovial Tissue/Fluid and Peripheral Blood from Patients with Rheumatoid Arthritis or Lyme Arthritis [C] . Qi Wang, Elise E. Drouin, Chunxiang Yao, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：免疫原性HLA-DR呈递肽，从类风湿性关节炎或莱姆关节炎患者的滑膜组织/液体和外周血的临床样本中鉴定出来
5. Clinical studies of immunomodulatory activities of Yunzhi -Danshen in breast cancer and nasopharyngeal carcinoma patients, and Lingzhi-San Miao San in rheumatoid arthritis patients. [D] . Bao, Yixi. 2005

机译：云芝丹参对乳腺癌和鼻咽癌患者及类风湿关节炎灵芝三妙散的免疫调节活性的临床研究。
6. Original article: Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis [O] . Paul Emery, Ricardo Blanco, Jose Maldonado Cocco, 2017

机译：原始文章：Baricitinib在常规合成DMARD难治性类风湿关节炎患者中进行的III期临床研究报告的患者结果
7. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis [O] . Yoshiya Tanaka, Bruno Fautrel, Edward C Keystone, 2019

机译：由于非反应和/或研究设计，从Adalimumab转换为Baricitinib的患者的临床结果：类风湿性关节炎患者的III期数据

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

摘要

著录项

相似文献

相关主题

期刊订阅